Codexis Inc. (NASDAQ:CDXS)’s share price was down 3.7% during mid-day trading on Thursday . The stock traded as low as $4.15 and last traded at $4.16, with a volume of 108,408 shares trading hands. The stock had previously closed at $4.32.

Several equities analysts have recently issued reports on CDXS shares. HC Wainwright started coverage on shares of Codexis in a research note on Wednesday, June 1st. They set a “buy” rating and a $6.00 price target for the company. Zacks Investment Research downgraded shares of Codexis from a “hold” rating to a “sell” rating in a research note on Monday, July 18th.

The stock’s market capitalization is $169.68 million. The firm has a 50 day moving average of $4.14 and a 200-day moving average of $3.80.

Codexis (NASDAQ:CDXS) last released its quarterly earnings results on Monday, May 9th. The company reported ($0.11) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.04. During the same period in the prior year, the firm earned ($0.07) EPS. The company earned $8 million during the quarter, compared to analysts’ expectations of $7.49 million. Codexis’s quarterly revenue was up 17.6% on a year-over-year basis. On average, equities analysts anticipate that Codexis Inc. will post ($0.23) EPS for the current year.

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.